Johan Hansson
Karolinska Institutet · 187 works · 16,366 citations · h-index 55
Top works
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
- Sequence variants at the TERT-CLPTM1L locus associate with many cancer types
- NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing
- NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
- FBXW7/hCDC4 Is a General Tumor Suppressor in Human Cancer
- Genome-wide association study identifies three loci associated with melanoma risk
- New common variants affecting susceptibility to basal cell carcinoma
- Cisplatin Induces Endoplasmic Reticulum Stress and Nucleus-independent Apoptotic Signaling
- Skin Cancer Identification Using Multifrequency Electrical Impedance—A Potential Screening Tool
- Repair synthesis by human cell extracts in DNA damaged bycis- andtrans-diamminedichloroplatinum(II)
- Localization of DNA repair synthesis by human cell extracts to a short region at the site of a lesion
- Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial
- High-risk Melanoma Susceptibility Genes and Pancreatic Cancer, Neural System Tumors, and Uveal Melanoma across GenoMEL
- Screening of Germline Mutations in the CDKN2A and CDKN2B Genes in Swedish Families With Hereditary Cutaneous Melanoma
- Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents
- Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression.
- Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
- Suffering in silence: a qualitative study of second victims of adverse events